Log in or register to see all Alerts
New HTA Decisions in England
March 2021
Drug name
BLINCYTO® (blinatumomab)
Company
Amgen UK
Decision date
//
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.